[Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience].

Zherebtsova, V A; Vorobyev, V I; Gemdzhian, E G; Ulyanova, M A; Chernikov, M V; Ivanova, V L; Vinogradova, O Y; Ptushkin, V V

Zherebtsova, V A; Vorobyev, V I; Gemdzhian, E G; Ulyanova, M A; Chernikov, M V; Ivanova, V L; Vinogradova, O Y; Ptushkin, V V.

Affiliation

Zherebtsova VA; Botkin City Clinical Hospital.
Vorobyev VI; Botkin City Clinical Hospital.
Gemdzhian EG; National Research Center for Hematology.
Ulyanova MA; Botkin City Clinical Hospital.
Chernikov MV; Research Institute of Health Organization and Medical Management.
Ivanova VL; Botkin City Clinical Hospital.
Vinogradova OY; Botkin City Clinical Hospital.
Ptushkin VV; Botkin City Clinical Hospital.

Ter Arkh ; 93(7): 785-792, 2021 Jul 23.

Article in Ru | MEDLINE | ID: mdl-36286729

Subject(s)

Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Multiple Myeloma; Humans; Middle Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Dexamethasone/adverse effects; Lenalidomide/adverse effects; Multiple Myeloma/diagnosis; Multiple Myeloma/drug therapy

Key words

autologous transplant; carfilzomib; lenalidomide; real-life experience; relapsed/refractory multiple myeloma

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Angiogenesis Inhibitors / Multiple Myeloma Type of study: Diagnostic_studies Limits: Humans / Middle aged Language: Ru Journal: Ter Arkh Year: 2021 Document type: Article Country of publication: RUSSIA

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google